<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518059</url>
  </required_header>
  <id_info>
    <org_study_id>20181189</org_study_id>
    <secondary_id>1U01NS112010-01</secondary_id>
    <nct_id>NCT04518059</nct_id>
  </id_info>
  <brief_title>Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism</brief_title>
  <official_title>Assessing Skin Biomarkers for Preclinical Diagnosis of PD and Non-PD Parkinsonism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Banner Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Autonoma de San Luis Potos√≠</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether identification of misfolded proteins in the&#xD;
      skin will help to determine what sort of parkinsonism someone has. We seek to demonstrate&#xD;
      whether someone has a synucleinopathy such as Parkinson's disease (PD), multiple system&#xD;
      atrophy (MSA), or dementia with Lewy bodies(DLB), as opposed to a tauopathy such as&#xD;
      progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD) or no parkinsonism at&#xD;
      all (control).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a clinical research study for patients with parkinsonism, including Parkinson's&#xD;
      disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy,&#xD;
      and dementia with Lewy bodies. Parkinsonism can be difficult to diagnose, especially in the&#xD;
      early stages of the disease. Skin punch biopsy could be a useful and way to diagnose and&#xD;
      measure the severity of these conditions. Given that there currently is no proven way to&#xD;
      determine that someone has a synucleinopathy such as PD and not a tauopathy, this is a novel&#xD;
      study that may lead to better ways to diagnose people with parkinsonism. The purpose of the&#xD;
      study is to identify changes on a skin punch biopsy, in which small samples of skin are&#xD;
      removed and sent to the laboratory for examination. We are seeking to measure the amount of&#xD;
      misfolded alpha-synuclein in someone's skin. Participation will last between 1 and 2 years&#xD;
      and will involve between 2 and 4 visits. Visits will include a physical examination,&#xD;
      questionnaires, a memory test, blood draws, and a single visit for skin punch biopsies. We&#xD;
      will also be looking to enroll volunteers to serve as &quot;controls,&quot; who do not have any&#xD;
      neurological illness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Amount of alpha-synuclein in the skin</measure>
    <time_frame>Cross-sectional at baseline</time_frame>
    <description>Alpha-synuclein will be measured by RT-QuIC and sPMCA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PSPRS measures of progressive supranuclear palsy (PSP) severity in people with PSP</measure>
    <time_frame>Baseline, 1 year, and optional 2 year assessment</time_frame>
    <description>Questionnaire and examination. Lower scores are better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in UMSARS measures of multiple system atrophy (MSA) severity in people with MSA</measure>
    <time_frame>Baseline, 1 year, and optional 2 year assessment</time_frame>
    <description>Questionnaire and examination. Lower scores are better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hoehn and Yahr (H&amp;Y) and modified H&amp;Y Scores</measure>
    <time_frame>Baseline, 1 year, and optional 2 year assessment</time_frame>
    <description>Zero to 5 parkinsonism rating scale score. Lower score is better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Schwab and England (S&amp;E) Score</measure>
    <time_frame>Baseline, 1 year, and optional 2 year assessment</time_frame>
    <description>0% to 100% rating scale score. Higher score is better.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>Baseline, 1 year, and optional 2 year assessment</time_frame>
    <description>Zero to 30 cognitive rating scale score. Higher score is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>Baseline, 1 year, and optional 2 year assessment</time_frame>
    <description>Zero to 24 sleepiness rating scale score. Lower score is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton depression scale</measure>
    <time_frame>Baseline, 1 year, and optional 2 year assessment</time_frame>
    <description>17 item depression rating scale score. Lower score is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton anxiety scale</measure>
    <time_frame>Baseline, 1 year, and optional 2 year assessment</time_frame>
    <description>14 item depression rating scale score. Lower score is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in REM Behavior Disorder Questionnaire</measure>
    <time_frame>Baseline, 1 year, and optional 2 year assessment</time_frame>
    <description>10 item depression rating scale score. Lower score is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure with orthostatic posture</measure>
    <time_frame>Baseline, 1 year, and optional 2 year assessment</time_frame>
    <description>Blood pressure from lying down to sitting to standing. Smaller drop in blood pressure is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of alpha-synuclein in the blood</measure>
    <time_frame>Baseline, optional 1 year assessment, and optional 2 year assessment</time_frame>
    <description>Alpha-synuclein will be measured in the blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PDQ-39</measure>
    <time_frame>Baseline, optional 1 year assessment, and optional 2 year assessment</time_frame>
    <description>39 item health status questionnaire. Lower is better.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Parkinsonism</condition>
  <condition>Dementia With Lewy Bodies</condition>
  <condition>Multiple System Atrophy</condition>
  <condition>Progressive Supranuclear Palsy</condition>
  <condition>Corticobasal Degeneration</condition>
  <arm_group>
    <arm_group_label>Parkinsonism Group</arm_group_label>
    <description>Participants with Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Participants without parkinsonism</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>punch skin biopsy</intervention_name>
    <description>An anesthetic medication is injected to numb the areas of skin and two samples of skin are obtained from punch biopsy.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Parkinsonism Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Skin and blood samples are collected and used for analysis in the Case Western Reserve&#xD;
      University Department of Pathology. Blood samples are obtained for NIH affiliated biobanks&#xD;
      BioSEND/PDBP and RUCDR.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People with parkinsonism, Parkinson's disease (PD), dementia with Lewy bodies (DLB),&#xD;
        multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal&#xD;
        degeneration (CBD), and also controls without parkinsonism.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 21 years old and age &lt;90 years of age at the time of the baseline visit 1&#xD;
&#xD;
          -  Age of diagnosis at least 40 years old for PD, DLB, and PSP and at least 30 years old&#xD;
             for MSA&#xD;
&#xD;
          -  A confirmed diagnosis of PD, PSP, CBD, MSA, DLB, or healthy control&#xD;
&#xD;
          -  Montreal Cognitive Assessment (MoCA) &gt; 10 at the outset of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age 90 or above&#xD;
&#xD;
          -  Allergy to local anesthetic&#xD;
&#xD;
          -  History of deep brain stimulation (DBS) or other brain surgery prior to Visit 1&#xD;
&#xD;
          -  For PD or DLB diagnoses, any other neurodegenerative or central nervous system process&#xD;
             that would interfere with examination&#xD;
&#xD;
          -  For PD or DLB, history of negative DATscan&#xD;
&#xD;
          -  Use of investigational drugs or devices within 60 days prior to baseline visit (except&#xD;
             for dietary supplements)&#xD;
&#xD;
          -  In control subjects, family history of a neurodegenerative disease in a first degree&#xD;
             or second degree blood relative&#xD;
&#xD;
          -  History of schizophrenia&#xD;
&#xD;
          -  History of antipsychotic medication use or exposure in controls or history of&#xD;
             antipsychotic medication leading to parkinsonism (drug induced parkinsonism) in the&#xD;
             parkinsonism group&#xD;
&#xD;
          -  Blood clotting disorder&#xD;
&#xD;
          -  On multiple (more than one) antiplatelet and/or anticoagulant blood thinner&#xD;
             medications in combination (except for aspirin if it can be safely held for 1 week)&#xD;
&#xD;
          -  Any other medical, psychiatric, or cognitive illness that in the investigator's&#xD;
             opinion would interfere with cooperation or ability to undergo the study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenquan Zou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Gunzler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center and Case Western Reserve University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chen Shu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisar Khawam</last_name>
    <phone>216-844-2493</phone>
    <email>Elisar.Khawam@UHhospitals.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven Gunzler, MD</last_name>
    <phone>216-844-8685</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Gunzler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Steven Gunzler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Suburban Health Center</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Gunzler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Steven Gunzler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>February 7, 2021</last_update_submitted>
  <last_update_submitted_qc>February 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Steven Gunzler, MD</investigator_full_name>
    <investigator_title>Assistant Professor, Neurology</investigator_title>
  </responsible_party>
  <keyword>Parkinson disease</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>dementia with Lewy bodies</keyword>
  <keyword>multiple system atrophy</keyword>
  <keyword>progressive supranuclear palsy</keyword>
  <keyword>corticobasal degeneration</keyword>
  <keyword>biomarker</keyword>
  <keyword>parkinsonism</keyword>
  <keyword>alpha-synuclein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

